Targeted Therapy of Oral Squamous Cell Carcinoma with Cancer Cell Membrane Coated Co‐Fc Nanoparticles Via Autophagy Inhibition
Source abstract
Abstract
Abstract Systemic chemotherapy for oral squamous cell carcinoma (OSCC) is associated with multidrug resistance and systemic adverse effects. Cobalt‐ferrocene metal–organic framework (Co‐Fc) is a nanoparticle synthetized by ferrocene and cobalt with a stronger Fenton reaction that can locally generate hydroxyl radical and effectively kill tumors. However, tumor cells can remove exogenous substances through autophagy activity to maintain the internal environment homeostasis. Herein, Co‐Fc loaded with the classical autophagy inhibitor hydroxychloroquine (HCQ) to construct Co‐Fc@HCQ nanoparticles is synthetized. The ferrocene in Co‐Fc catalyzes the production of endogenous reactive oxygen species (ROS) through the Fenton reaction. The presence of HCQ inhibits the fusion of autophagy vesicles with lysosomes and reduces the scavenging of ROS. In addition, to enhance the tumor targeting effect of Co‐Fc@HCQ nanoparticles, oral cancer cell membranes (CM) are extracted from CAL‐27 cell line to construct CM@Co‐Fc@HCQ nanoparticles with good homologous targeting and immune escape effects. The results prove the good tumor targeting, biosafety as well as the therapeutic effect of CM@Co‐Fc@HCQ. In conclusion, via specific tumor targeting and local autophagy‐conducted ROS boosting, CM@Co‐Fc@HCQ nanoparticles, a smart local delivery chemo‐dynamic substance, provide a promising approach for effectively treating OSCC.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Autophagy in Disease and Therapy · Advanced Nanomaterials in Catalysis · Metal-Organic Frameworks: Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Stomatology Hospital School of Stomatology Zhejiang University School of Medicine Clinical Research Center for Oral Diseases of Zhejiang Province Key Laboratory of Oral Biomedical Research of Zhejiang Province Cancer Center of Zhejiang University Hangzhou 310006 P. R. China
Department of Surgery The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang 310009 China
References (31)
Show source-provided references
1. 10.1038/s41572-020-00224-310.1038/s41572-020-00224-3 ↗
2. 10.1200/JCO.2016.71.117610.1200/JCO.2016.71.1176 ↗
3. 10.1056/NEJMoa150600710.1056/NEJMoa1506007 ↗
4. Furness S. · Cochrane Database Syst. Rev. · 2011 · 12
5. 10.7150/jca.3104510.7150/jca.31045 ↗
6. 10.1038/s41568-021-00435-010.1038/s41568-021-00435-0 ↗
7. 10.1002/adma.20170736510.1002/adma.201707365 ↗
8. 10.1016/j.envint.2020.10627310.1016/j.envint.2020.106273 ↗
9. 10.1039/D0DT01882A10.1039/D0DT01882A ↗
10. 10.1016/j.cell.2011.10.02610.1016/j.cell.2011.10.026 ↗
11. 10.1038/nrc.2017.5310.1038/nrc.2017.53 ↗
12. 10.1038/s41584-020-0372-x10.1038/s41584-020-0372-x ↗
13. 10.1172/JCI7045410.1172/JCI70454 ↗
14. 10.1016/j.biomaterials.2010.03.03510.1016/j.biomaterials.2010.03.035 ↗
15. 10.1002/adma.20170675910.1002/adma.201706759 ↗
16. 10.1002/advs.20210024110.1002/advs.202100241 ↗
17. 10.3389/fmolb.2021.72037010.3389/fmolb.2021.720370 ↗
18. 10.1186/s12943-020-1138-410.1186/s12943-020-1138-4 ↗
19. 10.7150/ijbs.6566910.7150/ijbs.65669 ↗
20. 10.1016/j.ccell.2020.06.00110.1016/j.ccell.2020.06.001 ↗
21. 10.1016/j.semcdb.2017.05.02310.1016/j.semcdb.2017.05.023 ↗
22. 10.7150/thno.4672810.7150/thno.46728 ↗
23. 10.1038/s41580-020-0230-310.1038/s41580-020-0230-3 ↗
24. 10.1016/j.cell.2005.02.00110.1016/j.cell.2005.02.001 ↗
25. 10.1038/4345910.1038/43459 ↗
26. 10.1038/nrc.2017.5310.1038/nrc.2017.53 ↗
27. 10.1016/j.canlet.2014.09.02010.1016/j.canlet.2014.09.020 ↗
28. Tan W. X. · Oncol. Rep. · 2019 · 42 · 1343
29. 10.1186/s12943-020-1138-410.1186/s12943-020-1138-4 ↗
30. 10.4161/auto.2639810.4161/auto.26398 ↗
31. 10.1158/1078-0432.CCR-11-128210.1158/1078-0432.CCR-11-1282 ↗